Investigate patient assistance programs
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
10.1161/ATVBAHA.110.206425
About 61% of GLP - 1 users in the study were taking the drugs to treat type 2 diabetes, while about 39% of users generally younger, wealthier and fewer clinically obese users were using them to manage their weight
So this shows that theres a potential for strong glycemic control with a fraction of the GI side effects and also no need for any dose up titration
Always use the peptide calculator to verify before drawing
